Astrazeneca (AZN) Intangibles (2009 - 2026)

Astrazeneca has reported Intangibles for 18 years, with the latest figure at $37.7 billion in Q2 2026.

• On a quarterly basis, Intangibles fell 0.53% year-over-year to $37.7 billion in Q2 2026; TTM through Jun 2026 was $37.7 billion, a 0.53% decrease from a year earlier, with the FY2025 full-year figure at $37.8 billion, up 1.8% from the prior year.
• Intangibles was $37.7 billion for Q2 2026 at Astrazeneca, up from $36.9 billion in the prior quarter.
• The five-year high for Intangibles was $41.3 billion in Q1 2022, with the low at $36.9 billion in Q1 2026.
• Average Intangibles over 5 years is $38.6 billion, with a median of $38.3 billion recorded in 2023.
• The largest YoY upside for Intangibles was 102.81% in 2022 against a maximum downside of 10.25% in 2022.
• Over 5 years, Intangibles stood at $39.3 billion in 2022, then retreated by 3.1% to $38.1 billion in 2023, then slipped by 2.39% to $37.2 billion in 2024, then increased by 1.8% to $37.8 billion in 2025, then retreated by 0.33% to $37.7 billion in 2026.
• The last three Intangibles figures came in at $37.7 billion (Q2 2026), $36.9 billion (Q1 2026), and $37.8 billion (Q4 2025), per Business Quant data.